scholarly journals Kidney Exchange to Overcome Financial Barriers to Kidney Transplantation

2016 ◽  
Vol 17 (3) ◽  
pp. 782-790 ◽  
Author(s):  
M. A. Rees ◽  
T. B. Dunn ◽  
C. S. Kuhr ◽  
C. L. Marsh ◽  
J. Rogers ◽  
...  
2021 ◽  
Vol 118 (36) ◽  
pp. e2106652118
Author(s):  
Afshin Nikzad ◽  
Mohammad Akbarpour ◽  
Michael A. Rees ◽  
Alvin E. Roth

Kidney failure is a worldwide scourge, made more lethal by the shortage of transplants. We propose a way to organize kidney exchange chains internationally between middle-income countries with financial barriers to transplantation and high-income countries with many hard to match patients and patient–donor pairs facing lengthy dialysis. The proposal involves chains of exchange that begin in the middle-income country and end in the high-income country. We also propose a way of financing such chains using savings to US health care payers.


Kidney360 ◽  
2020 ◽  
Vol 1 (11) ◽  
pp. 1291-1299
Author(s):  
Krista L. Lentine ◽  
John D. Peipert ◽  
Tarek Alhamad ◽  
Yasar Caliskan ◽  
Beatrice P. Concepcion ◽  
...  

BackgroundTransplant practices related to use of organs from hepatitis C virus–infected donors (DHCV+) is evolving rapidly.MethodsWe surveyed US kidney transplant programs by email and professional society LISTSERV postings between July 2019 and January 2020 to assess attitudes, management strategies, and barriers related to use of viremic (nucleic acid testing positive [NAT+]) donor organs in recipients who are not infected with HCV.ResultsStaff at 112 unique programs responded, representing 54% of US adult kidney transplant programs and 69% of adult deceased donor kidney transplant volume in 2019. Most survey respondents were transplant nephrologists (46%) or surgeons (43%). Among the responding programs, 67% currently transplant DHCV antibody+/NAT− organs under a clinical protocol or as standard of care. By comparison, only 58% offer DHCV NAT+ kidney transplant to recipients who are HCV−, including 35% under clinical protocols, 14% as standard of care, and 9% under research protocols. After transplant of DHCV NAT+ organs to recipients who are uninfected, 53% start direct-acting antiviral agent (DAA) therapy after discharge and documented viremia. Viral monitoring protocols after DHCV NAT+ to HCV uninfected recipient kidney transplantation varied substantially. 56% of programs performing these transplants report having an institutional plan to provide DAA treatment if declined by the recipient’s insurance. Respondents felt a mean decrease in waiting time of ≥18 months (range, 0–60) justifies the practice. Program concerns related to use of DHCV NAT+ kidneys include insurance coverage concerns (72%), cost (60%), and perceived risk of transmitting resistant infection (44%).ConclusionsAddressing knowledge about safety and logistic/financial barriers related to use of DHCV NAT+ kidney transplantation for recipients who are not infected with HCV may help reduce discards and expand the organ supply.PodcastThis article contains a podcast at https://www.asnonline.org/media/podcast/K360/2020_11_25_KID0004592020.mp3


2004 ◽  
Vol 171 (4S) ◽  
pp. 494-494
Author(s):  
Michio Michio Nojima ◽  
Tetsuro Yoshimoto ◽  
Atsushi Nakao ◽  
Takuo Maruyama ◽  
Hidekazu Takiuchi ◽  
...  

2004 ◽  
Vol 171 (4S) ◽  
pp. 491-492
Author(s):  
William C. Nahas ◽  
Paulo R. Gianini ◽  
Luiz B. Saldanha ◽  
Eduardo Mazzucchi ◽  
Joannis Antonopoulos ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document